Floatz logo

Tisagenlecleucel

High-grade B-cell Lymphoma

NeoImmuneTechCell therapyPhase 1/2Active
CCC
51/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
44/ 100
Competitive Position
73/ 100

Competitive context

32 Active assets in the High-grade B-cell Lymphoma cohort.

Asset / SponsorPhaseRating
DEXAMETHASONE
City of Hope Medical Center
Phase 3BB
Cyclophosphamide
National Cancer Institute (NCI)
Phase 3BB
(+)-VINCRISTINE
OHSU Knight Cancer Institute
Phase 3BB
Cytosin-Arabinosid
City of Hope Medical Center
Phase 3B
Eloxatin
National Cancer Institute (NCI)
Phase 2B

View all 41 →

Same molecule, other indications

Tisagenlecleucel is also rated in:

non-Hodgkin lymphomaDormant
BB
Indicative ·
66 / 100
View asset →
Diffuse Large B Cell LymphomaDormant
BB
Indicative ·
64 / 100
View asset →
B-cell Acute Lymphoblastic LeukemiaDormant
BB
Indicative ·
64 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →